NEO / NeoGenomics (NEO) CEO, Mark Mallon on Q4 2021 Results - Earnings Call Transcript

NeoGenomics ( NEO ) is a small-cap provider of cancer genetics diagnostics. They boast one of the most comprehensive oncology-focused testing menus in more_horizontal

FT. MYERS, FL / ACCESSWIRE / October 17, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research se more_horizontal

NeoGenomics (NEO) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might dr more_horizontal

NeoGenomics, Inc (NASDAQ:NEO ) Q2 2023 Earnings Conference Call August 8, 2023 8:30 AM ET Company Participants Kendra Sweeney - Vice President, Invest more_horizontal

Although the revenue and EPS for NeoGenomics (NEO) give a sense of how its business performed in the quarter ended June 2023, it might be worth consid more_horizontal

Today, we take our first look at NeoGenomics, Inc., a company focused on oncology testing. NeoGenomics has strung together a series of strong quarterl more_horizontal

NeoGenomics, Inc. (NASDAQ:NEO ) Q1 2023 Earnings Conference Call May 8, 2023 4:30 PM ET Company Participants Kendra Sweeney - VP of IR Chris Smith - C more_horizontal

NeoGenomics, Inc. (NASDAQ:NEO ) Q4 2022 Earnings Conference Call February 23, 2023 8:30 AM ET Company Participants Chris Smith - Chief Executive Offic more_horizontal